Print this article

Vítor Sousa – Senior Manager, R&D Biological Division, Cerbios-Pharma SA, Cerbios

Keywords:

e-version image

Click HERE to download the PDF version



 

WHICH ARE THE TRENDS THAT WILL CHARACTERIZE THE ANTIBODY-DRUG CONJUGATES (ADCS) SECTOR?

ADCs are advanced chemotherapy treatments in which the cytotoxic payload targets the tumor cell by means of an antibody. The specificity and affinity of the antibody molecule combined is the key to the safe delivery of the toxic payload into the cell overexpressing a certain tumor -associated antigen at its surface. 

The previous generation of ADC payloads (dominated by Auristatins and Maytansinoids) is now being superseded by new classes of toxins that are more potent than those currently available (with a potency in the picomolar range or lower) and will help to further reduce doses. 

As a CDMO, Cerbios-Pharma SA (hereinafter “CERBIOS”) is already experiencing this change as it wor ... ...